The Effect of Renal Dysfunction on Circulating Sclerostin Level in Patients with Type 2 Diabetes

sebaie, Mahmoud hamdy El; arafat, mohamed abbas; Fawzy, Mohamed S; salem, ibrahim

doi:10.21608/zumj.2020.16472.1477

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most importantly, eGFR is signi cantly and inversely associated with DKK1 and sclerostin, and positively with β-catenin and a composite score indicating the ratio between stimulators/antagonists of the Wnt-pathway. These results extend those of a previous study showing a negative association between GFR and sclerostin 32,59 . In CKD patients, sclerostin was associated with indicants of in ammation and vascular damage 31,50 and negatively correlated with histomorphometric parameters of bone turnover and osteoblast numbers 60 .…”

Section: Discussionsupporting

confidence: 91%

Wnt/β-Catenin Pathway Proteins in End-Stage Renal Disease

2021

View full text Add to dashboard Cite

Aim: To delineate the association of end-stage renal disease (ESRD) and Wnt-proteins including the agonist R-spondin-1, the transducer β-catenin and the antagonists DKK1 and sclerostin. Materials & methods: Serum Wnt-pathway proteins levels were measured by ELISA in 60 ESRD patients and 30 normal controls. Results: DKK1 and sclerostin were significantly higher in ESRD than in controls, and β-catenin and the catenin + R-sponin-1/DKK1 + sclerostin ratio, reflecting the ratio of agonist and transducer on antagonists (AT/ANTA), were significantly lower in ESRD. Estimated glomerular filtration rate was significantly associated with DKK1 and sclerostin (inversely), β-catenin (positively) and the AT/ANTA ratio (r = 0.468, p < 0.001). Conclusion: Wnt/β-catenin pathway proteins show significant alterations in ESRD, indicating significantly increased levels of antagonists.

show abstract

Section: Discussionsupporting

confidence: 91%

Wnt/β-Catenin Pathway Proteins in End-Stage Renal Disease

2021

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 91%

Wnt/β-catenin pathway proteins in end-stage renal disease

Al‐Hakeim

Asad

Maes

2021

Preprint

View full text Add to dashboard Cite

Background. Wnt-pathway proteins play a vital role in kidney development and defects in the Wnt-pathway are associated with kidney disorders. However, the knowledge on the role of Wnt/β-catenin pathway proteins in end-stage renal disease (ESRD) is limited.Aim of the study. To delineate the association of ESRD and Wnt-proteins including the agonistR-spondin 1, the transducer β-catenin and the antagonists Dickkopf-related protein 1 (DKK1) and sclerostin.Methods. Serum Wnt-pathway proteins levels were measured by ELISA, while other biochemicals were measured spectrophotometrically in 60 ESRD patients and 30 normal controls.Results. DKK1 and sclerostin were significantly higher in ESRD than in controls, and β-catenin and the catenin + R-Sponin-1 / DKK1 + sclerostin ratio, reflecting the ratio of agonist and transducer / antagonists (AT/ANTA), were significantly lower in ESRD. Logistic regression analysis showed that ESRD was significantly predicted by increased levels of DDK1 and sclerostin and lowered β-catenin (p<0.001). eGFR was significantly associated with DKK1 and sclerostin (inversely), β-catenin (positively) and the AT/ANTA ratio (r=0.468, p<0.001). DKK1 levels were significantly and positively correlated with urea, creatinine, and copper. DKK1 and sclerostin were inversely associated with hemoglobin and packet cell volume. Catenin was significantly negatively associated with copper, urea and creatinine.Conclusion. Wnt/β-catenin pathway proteins show significant alterations in ESRD, indicating significantly increased levels of antagonists and, therefore, attenuated Wnt/β-catenin pathway activity. The latter is associated with lowered eGFR and increased serum copper levels. Wnt/β-catenin pathway proteins are possible drug targets to treat ESRD or its consequences.

show abstract

The Effect of Renal Dysfunction on Circulating Sclerostin Level in Patients with Type 2 Diabetes

Cited by 2 publications

References 0 publications

Wnt/β-Catenin Pathway Proteins in End-Stage Renal Disease

Wnt/β-Catenin Pathway Proteins in End-Stage Renal Disease

Wnt/β-catenin pathway proteins in end-stage renal disease

Contact Info

Product

Resources

About